Neurocrine Biosciences (NBIX) Expected to Post Quarterly Earnings on Thursday

Neurocrine Biosciences (NASDAQ:NBIX) is expected to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $1.64 per share and revenue of $890.05 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Neurocrine Biosciences Stock Up 0.4%

Shares of NBIX opened at $176.41 on Tuesday. The stock has a market capitalization of $17.74 billion, a P/E ratio of 27.18, a PEG ratio of 0.74 and a beta of 0.39. Neurocrine Biosciences has a twelve month low of $122.14 and a twelve month high of $181.18. The firm has a fifty day simple moving average of $165.91 and a two-hundred day simple moving average of $145.29.

Insiders Place Their Bets

In other news, insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction on Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the transaction, the insider owned 25,846 shares in the company, valued at $4,141,821.50. This trade represents a 29.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total value of $5,770,298.14. Following the sale, the insider directly owned 22,374 shares of the company’s stock, valued at $3,495,266.28. This represents a 62.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 394,172 shares of company stock valued at $62,221,181. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in Neurocrine Biosciences by 83.7% in the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after acquiring an additional 1,263,633 shares during the last quarter. Zurich Insurance Group Ltd FI bought a new position in shares of Neurocrine Biosciences during the 4th quarter valued at approximately $65,162,000. Two Sigma Investments LP bought a new position in shares of Neurocrine Biosciences during the 3rd quarter valued at approximately $48,791,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Neurocrine Biosciences in the second quarter valued at $42,933,000. Finally, Northern Trust Corp grew its holdings in shares of Neurocrine Biosciences by 31.9% in the fourth quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock valued at $173,201,000 after purchasing an additional 295,470 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several recent research reports. Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Weiss Ratings downgraded shares of Neurocrine Biosciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, July 10th. Morgan Stanley increased their price target on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Canaccord Genuity Group lifted their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Finally, Wedbush boosted their price objective on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $194.05.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.